<DOC>
	<DOCNO>NCT00243971</DOCNO>
	<brief_summary>The objective trial compare effect rotigotine ( SPM 962 ) ropinirole control early morning motor impairment sleep disorder subject early-stage PD . Subjects meet eligibility criterion randomly assign either rotigotine transdermal patch ropinirole tablet . Trial medication titrate rotigotine ropinirole individual optimal dose achieve . Following Titration period 4 week rotigotine arm 6 week ropinirole arm , subject maintain optimal maximal dose 4 week . At end Maintenance period , subject give opportunity enter 2-year rotigotine patch extension trial . The first subject enrol December 2004 . The last subject enrol June 2005 . Last subject expect October 2005 . The trial still ongoing .</brief_summary>
	<brief_title>A Trial Compare Efficacy Rotigotine Transdermal Patch That Ropinirole Early Morning Motor Impairment Sleep Disorders Subjects With Early-Stage , Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Earlystage , idiopathic Parkinson 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>EARLY-STAGE , IDIOPATHIC PARKINSON 'S DISEASE</keyword>
</DOC>